Робоча програма і методичні вказівки до самостійного вивчення дисципліни "Основи теорії транспорту"

Гірничовидобувна промисловість України набуває розвитку на базі без- перервного використання досягнень науково-технічного прогресу, застосування комплексної механізації та автоматизації всіх процесів виробництва, поліпшен- ня якісних показників підприємств, підвищення продуктивності й безпеки пра- ці.Гірничовидобувна промисловість України набуває розвитку на базі без- перервного використання досягнень науково-технічного прогресу, застосування комплексної механізації та автоматизації всіх процесів виробництва, поліпшен- ня якісних показників підприємств, підвищення продуктивності й безпеки пра- ці

Effect of Regular Aerobic Exercise on Cognitive Function, Depression Level and Regulative Role of Neurotrophic Factor: A Prospective Cohort Study in the Young and the Middle-Aged Sample

Lingming Kong,1,* Liqin Miu,2,* Wenwei Yao,2 Zhiyuan Shi3 1Mental Health Research Center, No. 904th Hospital, Changzhou, Jiangsu, 213003, People’s Republic of China; 2Psychiatry Department, the 2nd People’s Hospital of Jintan District, Changzhou, Jiangsu, 213200, People’s Republic of China; 3College of Clinical Medicine, Yangzhou University, Yangzhou, Jiangsu, 225009, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lingming Kong, Mental Health Research Center, North Peace Road 55, No. 904th Hospital, Changzhou, Jiangsu, 213003, People’s Republic of China, Email [email protected]: Mild cognitive impairment (MCI) and depressive disorder (DD), which are associated with unhealthy lifestyles, are prevalent worldwide. This study aimed to investigate the effects of regular aerobic exercise on cognitive function, depression, and the regulatory role of neurotrophic growth factors for providing scientific basis in preventing MCI and DD in healthy individuals.Patients and Methods: Eighty members of the fitness center and 80 community residents were recruited, who were administered by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Patient Health Questionnaire (PHQ-9). Brain-derived neurotrophic factor (BDNF) and glial cell-line-derived neurotrophic factor (GDNF) in the peripheral blood were detected by enzyme-linked immunosorbent assay (ELISA).Results: The RBANS and other factor scores, except for visuospatial abilities, were higher and PHQ-9 scores were lower in the study group than in the control group. The concentrations of BDNF and GDNF in the study group were higher than those in the control group. RBANS and its factor scores positively and PHQ-9 negatively correlated with BDNF and GDNF levels. Finally, multiple regression analysis showed that BDNF, as a predictor of RBANS, could explain 59.90% of its variance and that GDNF was a predictor of PHQ-9 could explain 12.30% of the variance.Conclusion: Regular aerobic exercise can improve cognitive function and depressive symptoms by increasing the BDNF and GDNF levels.Keywords: cognitive impairment, depression level, brain derived neurotrophic factor, glial cell line-derived neurotrophic factor, aerobic exercis

Search for Chargino and Neutralino Production at sqrt(s) = 192-209 GeV at LEP

Approximately 438 pb-1 of e+e- data from the OPAL detector, taken with the LEP collider running at centre-of-mass energies of 192-209 Gev, are analyzed to search for evidence of chargino pair production, e+e- -> tilde chi^+_1 tilde chi^-_1, or neutralino associated production, e+e- -> tilde chi^0_2 tilde chi^0_1. Limits are set at the 95% confidence level on the product of the cross-section for the process e+e- -> tilde chi^+_1 tilde chi^-_1 and its branching ratios to topologies containing jets and missing energy, of jest with a lepton and missing energy, and on the product of the cross-section for e+e- -> tilde chi^0_2 tilde chi^0_1 and its branching ratio to jets. R-parity conservation is assumed throughout this paper. When these results are interpreted in the context of the Constrained Minimal Supersymmetric Standard Model, limits are also set on the masses of the tilde chi^+-_1, tilde chi^0_1 and tilde chi^0_2, and regions of the parameter space of the model are ruled out. Nearly model-independent limits are also set at the 95% confidence level on sigma(e+e- -> tilde chi^+_1 tilde chi^-_1) with the assumption that each chargino decays via a W boson, and on sigma(e+e- -> tilde chi^0_2 tilde chi^0_1) with the tilde chi^0_2 assumed to decay via a Z^0.Comment: 33 pages, 13 figures, Submitted to Eur Phys J.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.

BackgroundThe importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive marker in invasive breast cancer is well established. Accurate assessment of HER2 status is essential to determine optimal treatment options.MethodsBreast cancer tumor tissue samples from the VIRGO observational cohort tissue substudy that were locally HER2-negative were retested centrally with both US Food and Drug Administration (FDA)-approved immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays, using FDA-approved assay cutoffs; results were compared.ResultsOf the 552 unique patient samples centrally retested with local HER2-negative results recorded, tumor samples from 22 (4.0%) patients were determined to be HER2-positive (95% confidence interval [CI] = 2.5%-5.7%). Of these, 18 had been tested locally by only one testing methodology; 15 of 18 were HER2-positive after the central retesting, based on the testing methodology not performed locally. Compared with the 530 patients with centrally confirmed HER2-negative tumors, the 22 patients with centrally determined HER2-positive tumors were younger (median age 56.5 versus 60.0 years) and more likely to have ER/PR-negative tumors (27.3% versus 22.3%). These patients also had shorter median progression-free survival (6.4 months [95% CI = 3.8-15.9 months] versus 9.1 months [95% CI = 8.3-10.3 months]) and overall survival (25.9 months [95% CI = 13.8-not estimable] versus 27.9 months [95% CI = 25.0-32.9 months]).ConclusionsThis study highlights the limitations of employing just one HER2 testing methodology in current clinical practice. It identifies a cohort of patients who did not receive potentially efficacious therapy because their tumor HER2-positivity was not determined by the test initially used. Because of inherent limitations in testing methodologies, it is inadvisable to rely on a single test to rule out potential benefit from HER2-targeted therapy